CR20200616A - Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión - Google Patents

Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Info

Publication number
CR20200616A
CR20200616A CR20200616A CR20200616A CR20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A CR 20200616 A CR20200616 A CR 20200616A
Authority
CR
Costa Rica
Prior art keywords
bupropion
methods
modulating
plasma levels
tetrabenazine
Prior art date
Application number
CR20200616A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20200616A publication Critical patent/CR20200616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>Esta divulgación se refiere a métodos que administran bupropión, como <em>S</em>bupropión o <em>R</em>-bupropión, junto con tetrabenazina, alfa-dihidrotetrabenazina o betadihidrotetrabenazina a un ser humano. También se describen formas de dosificación, sistemas de administración de fármacos y métodos relacionados con tetrabenazina, alfadihidrotetrabenazina o beta-dihidrotetrabenazina y bupropión, como <em>S</em>-bupropión o <em>R</em>bupropión</p>
CR20200616A 2018-06-10 2019-06-10 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión CR20200616A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682998P 2018-06-10 2018-06-10
US201862683399P 2018-06-11 2018-06-11
PCT/US2019/036406 WO2019241162A1 (en) 2018-06-10 2019-06-10 Methods of modulating tetrabenazine metabolites plasma levels using bupropion

Publications (1)

Publication Number Publication Date
CR20200616A true CR20200616A (es) 2021-03-15

Family

ID=68843534

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200616A CR20200616A (es) 2018-06-10 2019-06-10 Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión

Country Status (17)

Country Link
EP (1) EP3790538A4 (es)
JP (2) JP2021529826A (es)
KR (2) KR20240034871A (es)
CN (1) CN112292121A (es)
AU (2) AU2019284477B2 (es)
BR (1) BR112020025064A2 (es)
CA (1) CA3101375A1 (es)
CL (1) CL2020003189A1 (es)
CO (1) CO2021000037A2 (es)
CR (1) CR20200616A (es)
EC (1) ECSP20082568A (es)
IL (1) IL279332A (es)
MX (1) MX2020013385A (es)
NI (1) NI202000095A (es)
PE (1) PE20210370A1 (es)
SG (1) SG11202011762VA (es)
WO (1) WO2019241162A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US10105327B2 (en) * 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US9707191B2 (en) * 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
MX2017017015A (es) * 2015-06-23 2018-02-26 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.

Also Published As

Publication number Publication date
CO2021000037A2 (es) 2021-01-18
PE20210370A1 (es) 2021-02-26
JP2024059744A (ja) 2024-05-01
KR20210018914A (ko) 2021-02-18
MX2020013385A (es) 2021-05-27
EP3790538A4 (en) 2021-06-30
CA3101375A1 (en) 2019-12-19
AU2019284477B2 (en) 2022-08-11
IL279332A (en) 2021-01-31
CN112292121A (zh) 2021-01-29
JP2021529826A (ja) 2021-11-04
BR112020025064A2 (pt) 2021-03-23
NI202000095A (es) 2021-06-22
SG11202011762VA (en) 2020-12-30
WO2019241162A1 (en) 2019-12-19
EP3790538A1 (en) 2021-03-17
CL2020003189A1 (es) 2021-05-28
KR20240034871A (ko) 2024-03-14
ECSP20082568A (es) 2021-02-26
AU2022268331A1 (en) 2022-12-15
AU2019284477A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019003098A (es) Composicion farmaceutica.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
EP3572070A4 (en) RETARD ACTIVE SUBSTANCE RELEASE SYSTEM FOR ANALGETIC LOCAL STUNNING AND MANUFACTURING METHOD AND APPLICATION THEREOF
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
CR20220355A (es) Compuestos activos frente a receptores nucleares
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
CR20200616A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
IN2013MU03370A (es)
EP3760250A4 (en) ADMINISTRATION DEVICE AND ADMINISTRATION SYSTEM FOR DRUG SOLUTION